Search Bar & Filters
Found 12 Actively Recruiting clinical trials
Actively Recruiting
Mechanical ventilation is often necessary for critically ill patients with acute brain injury, but how certain ventilator strategies like positive end-expiratory pressure PEEP and lung recruitment maneuvers affect brain function is not fully understood. This study aims to evaluate changes in brain electrical activity and cerebral blood flow during these ventilator interventions in neurocritical care patients. It investigates the relationship between ventilator settings and cerebral physiology to better understand brain-lung interactions in this population. Participants will undergo clinically indicated recruitment maneuvers and PEEP adjustments as part of their respiratory management. During these interventions, continuous monitoring using scalp electroencephalography EEG, transcranial Doppler ultrasound, invasive arterial blood pressure, end-tidal carbon dioxide, and other clinical variables will be performed. The study will record physiological data during baseline, intervention, and recovery periods lasting about 30 minutes to assess cerebral and systemic responses. Throughout the study, researchers will analyze EEG signals to assess cortical activity changes and measure cerebral blood flow velocity and neurovascular coupling. They will also monitor systemic hemodynamics and respiratory parameters to explore how ventilator-induced changes influence brain function. This comprehensive monitoring aims to inform future individualized ventilation strategies for patients with acute brain injury, with study participation lasting for the duration of these ventilator interventions and monitoring sessions.
Actively Recruiting
Stroke is one of the leading causes of death worldwide, with ischemic stroke being the most common type. Researchers are evaluating whether early administration of oral aspirin after intravenous thrombolysis improves functional outcomes for patients with acute ischemic stroke. The study aims to determine if starting aspirin treatment within 3 hours of thrombolysis can prevent neurological deterioration without increasing bleeding risks. Participants are randomly assigned to one of two groups the interventional group receives 300 mg of oral aspirin shortly after starting intravenous thrombolysis, while the control group receives a placebo. Both groups receive the best standard medical care according to current guidelines. Aspirin tablets may be chewed or given via a nasogastric tube if swallowing is difficult. The treatment is administered within 3 hours of initiating thrombolysis. During the study, participants are monitored for neurological improvements and potential complications using scales like the modified Rankin scale and NIH Stroke Scale at various time points up to 90 days after stroke. Researchers will assess functional outcomes, neurological changes, and safety measures, including the risk of intracranial hemorrhage. The total follow-up period extends to 90 days post-stroke.
Actively Recruiting
Researchers are evaluating telitacicept for adults with difficult-to-treat rheumatoid arthritis, a form of the disease not well controlled by standard treatments. This multicenter, open-label randomized trial aims to assess the safety and effectiveness of telitacicept over a 24-week treatment period, followed by a 2-week follow-up. The study involves patients whose disease remains active despite multiple disease-modifying therapies. Participants are randomly assigned to one of two groups one group receives weekly subcutaneous injections of 160 mg telitacicept along with standard therapy, while the other group continues with standard therapy alone. Standard therapy includes disease-modifying antirheumatic drugs, glucocorticoids, and non-steroidal anti-inflammatory drugs. The treatment period lasts for 24 weeks. During the study, participants will be regularly monitored through clinical assessments and laboratory tests to evaluate their response using measures like the ACR20 response rate at week 24. Researchers will also assess other disease activity indices and safety parameters. After the treatment period, participants have a 2-week follow-up to assess ongoing effects and safety. Total participation lasts about 26 weeks.
Actively Recruiting
Researchers are evaluating treatments for adults with HER2-positive advanced gastric or gastroesophageal junction adenocarcinoma that cannot be surgically removed or has spread to other parts of the body. This Phase II, randomized, open-label trial compares a combination of Disitamab Vedotin, Sintilimab, and S-1 against Trastuzumab plus chemotherapy with or without Sintilimab as first-line treatments. The study aims to assess which approach offers better results in controlling this type of stomach cancer. Participants will receive one of two treatment combinations. The experimental group is given Disitamab Vedotin intravenously every 3 weeks, Sintilimab intravenously every 3 weeks, and oral S-1 twice daily for 14 days in a 3-week cycle. The comparison group receives Trastuzumab intravenously with an initial loading dose followed by maintenance doses every 3 weeks, combined with chemotherapy drugs such as Oxaliplatin, Capecitabine, 5-FU, or Cisplatin, with or without Sintilimab. Treatments continue as per protocol to evaluate effectiveness and safety. Throughout the study, participants will undergo regular assessments to measure tumor response, progression-free survival, overall survival, duration of relief, and safety through monitoring adverse events. These evaluations include imaging scans to track measurable lesions based on RECIST 1.1 criteria, laboratory tests, and clinical examinations. The total study duration extends up to approximately two years, including follow-up for safety and outcomes, to gather comprehensive data on these treatment regimens.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of combining two drugs, iparomlimab and tuvonralimab QL1706, with chemotherapy to treat adults with HER2-negative, low PD-L1 expressing, unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma. This phase II trial focuses on patients whose cancer cannot be removed by surgery or has spread to other parts of the body. The study aims to understand how well this combination works and its safety profile in this specific group of patients. Participants will receive iparomlimab and tuvonralimab at a dose of 5 mgkg by intravenous drip on the first day of each 3-week cycle until disease progression or unacceptable side effects occur. They will also receive XELOX chemotherapy, which includes oxaliplatin given intravenously at 130 mgm2 on day 1 of each 3-week cycle for the first 6 cycles, and capecitabine tablets taken orally twice daily from days 1 to 14 of each cycle. This treatment continues until disease progression or intolerable toxicity. The study is a single-arm trial, meaning all participants receive this combination treatment. During the trial, researchers will monitor participants for progression-free survival over 12 months after the last participant joins, along with overall survival, response rates, duration of response, disease control rate, and safety through adverse event tracking for up to about 2 years. Participants will undergo regular assessments to measure tumor response and side effects. The total study period includes these follow-up evaluations to understand the treatments impact and safety profile comprehensively.
Actively Recruiting
Researchers are evaluating the effect, safety, and cost-effectiveness of low-sodium salt substitutes in reducing blood pressure and preventing hypertensive disorders in pregnant women at high risk in China. This study will enroll about 3,200 pregnant women at or before 16 weeks of gestation from multiple hospitals across several provinces. The trial uses an adaptive two-phase design, with an interim analysis after the first 400 participants to decide on continuation and sample size adjustments. Participants will be randomly assigned in equal groups to either use a potassium-enriched salt substitute containing 25% potassium chloride and 75% sodium chloride or continue using usual salt with over 99% sodium chloride. The assigned salt will be provided free of charge and used for home-prepared meals until delivery. Follow-up will continue through all antenatal visits and delivery to collect blood pressure data and monitor the incidence of hypertensive disorders and related adverse events. Participants will attend regular antenatal check-ups where blood pressure and other health data will be collected. The primary outcomes include the change in systolic blood pressure from baseline to about 36-37 weeks gestation and the incidence of new hypertensive disorders and maternal adverse events from randomization to delivery. Researchers will also assess safety, adherence, and cost-effectiveness during the study, which continues until delivery for each participant.
Actively Recruiting
Researchers are studying patients who have had an acute ischemic stroke caused by a blockage in a large blood vessel in the brain. The trial focuses on the safety and effectiveness of remote ischemic conditioning RIC as an additional treatment to improve recovery after endovascular thrombectomy, a procedure that removes the blockage. This research addresses the challenge that even when blood flow is restored, many patients still have poor outcomes or die, possibly due to brain injury during and after the procedure. The study compares three groups one receiving only endovascular thrombectomy and best medical care, a second group receiving thrombectomy plus RIC treatment for 14 days, and a third group receiving thrombectomy plus RIC for 30 days. RIC is a noninvasive device treatment where a cuff on the upper arm inflates and deflates in cycles, applied once before thrombectomy and twice daily afterward. Best medical management follows clinical guidelines for all groups. Participants will be monitored closely for 90 days after stroke. Researchers will assess recovery using the modified Rankin Scale to measure functional independence and will record neurological improvements, brain infarct size, adverse events, and quality of life. The study includes imaging, neurological exams, and safety checks at multiple time points, including 24 hours, 14 days, 72 hours, and 90 days post-treatment to evaluate the impact of RIC on stroke outcomes.
Actively Recruiting
Researchers are evaluating the use of topical 1.5% Ruxolitinib phosphate cream combined with systemic corticosteroids in patients aged 12 years and older who have active, progressive non-segmental vitiligo affecting the face. This prospective, multicenter, real-world observational study aims to assess the clinical effectiveness and safety of this combined treatment approach. The primary focus is on measuring improvement in facial vitiligo patches after 12 weeks of therapy. Participants will apply Ruxolitinib cream twice daily to affected skin areas for up to 24 weeks. Alongside this, they will receive corticosteroid therapy either by monthly intramuscular Compound Betamethasone injections or low-dose oral Dexamethasone pulses on weekends, also for a maximum of 24 weeks. Treatments are prescribed following standard clinical care practices, and the study plans to enroll 300 patients to monitor real-world outcomes. During the study, participants will be regularly followed up to evaluate improvements using the Facial Vitiligo Area Scoring Index F-VASI and other measures at multiple timepoints, including weeks 4, 8, 12, and 24. Safety and side effects will be monitored throughout the 24-week treatment. The main outcome is the proportion of patients achieving at least 75% improvement in facial vitiligo after 12 weeks. Overall, the study spans from initial treatment through to detailed clinical assessments and safety monitoring.
Actively Recruiting
Researchers are investigating the use of continuous positive airway pressure CPAP therapy after catheter ablation in adults with persistent atrial fibrillation AF who also have obstructive sleep apnea OSA. AF is a common irregular heart rhythm with high recurrence rates after ablation, and OSA is a modifiable risk factor that may influence AF recurrence. This study aims to determine whether CPAP therapy can reduce the return of atrial arrhythmias within one year compared to usual care. Participants will be randomly assigned to either a group receiving CPAP therapy plus usual care or a group receiving usual care alone. Those in the CPAP group will use the device for 12 months, with treatment settings adjusted by pressure titration and adherence monitored through device data. Usual care participants will receive standard AF management and education about OSA, with additional treatments permitted as needed. Follow-up includes ambulatory ECG monitoring at 3, 6, 9, and 12 months, alongside checkups conducted in person or by phone at 1, 3, 6, and 12 months. Throughout the study, participants will complete assessments of heart rhythm using ECG recorders over seven-day periods and answer questionnaires about quality of life and psychological health. Researchers will track the recurrence of atrial arrhythmias, medication use, further interventions, and AF burden. The main outcome measured is freedom from atrial arrhythmia recurrence within 12 months after randomization, with secondary outcomes evaluating arrhythmia patterns and patient well-being.
Actively Recruiting
Researchers are studying patients with osteoporotic fractures to find better prevention and treatment methods for refractures. This project involves registering patients for follow-up studies to collect epidemiological data and conducting prospective treatment studies. It aims to explore effective treatment strategies through randomized controlled trials and to develop warning models using biomarkers and new imaging technologies to predict osteoporotic refractures. Participants receive either denosumab alone or a sequential treatment starting with teriparatide followed by denosumab. Denosumab is given as a 60mg subcutaneous injection every six months for 24 months. Teriparatide is administered as a daily 20ug subcutaneous injection for either 6 or 12 months before switching to denosumab, which continues until the 24th month. These treatment plans are part of a multicenter randomized controlled trial. During the study, participants will be monitored for new vertebral fractures and changes in bone mineral density BMD at the lumbar spine, total hip, and femoral neck over 12 and 24 months. Blood tests will measure biomarkers related to bone turnover at several time points. Researchers will also track patients adherence to treatment and assess cost-effectiveness. Follow-up includes evaluation of new fractures at various sites and safety monitoring throughout the 24-month treatment period.
1-10 of 12
1